[Ustekinumab]

Ann Dermatol Venereol. 2019 Jun-Jul;146(6-7):497-502. doi: 10.1016/j.annder.2019.04.014. Epub 2019 Jun 14.

[Article in French]

Authors

D Jullien¹, D Staumont-Salle²; Groupe de recherche sur le psoriasis de la Société française de dermatologie³

Affiliations

¹ Service de dermatologie, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France. Electronic address: denis.jullien@chu-lyon.fr.
² Service de dermatologie, hôpital Claude-Huriez, CHR, rue Michel-Polonovski, 59000 Lille, France.
³ Service de dermatologie, hôpital Edouard-Herriot, 5, place d'Arsonval, 69003 Lyon, France; Service de dermatologie, hôpital Claude-Huriez, CHR, rue Michel-Polonovski, 59000 Lille, France.

PMID: 31208737
DOI: 10.1016/j.annder.2019.04.014

No abstract available

MeSH terms

Contraindications, Drug
Dermatologic Agents / pharmacology*
Female
Humans
Interleukin-12 / immunology
Interleukin-23 / immunology
Pregnancy
Psoriasis / drug therapy
Ustekinumab / pharmacology*
Vaccines, Attenuated / adverse effects

Substances

Dermatologic Agents
Interleukin-23
Vaccines, Attenuated
Interleukin-12
Ustekinumab